 Novocure Ltd NASDAQ: NVCR has entered into a clinical trial collaboration agreement with Roche Holdings AG OTC: RHHBY to develop Tumor Treating Fields TTFields together with Roches atezolizumab in metastatic pancreatic ductal adenocarcinoma mPDAC. The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as a first-line treatment for mPDAC. 